breast neoplasms


Summary: Tumors or cancer of the human BREAST.

Top Publications

  1. Wang W, Deng Z, Hatcher H, Miller L, Di X, Tesfay L, et al. IRP2 regulates breast tumor growth. Cancer Res. 2014;74:497-507 pubmed publisher
    ..These results suggest that dysregulation of IRP2 is an early nodal point underlying altered iron metabolism in breast cancer and may contribute to poor outcome of some patients with breast cancer...
  2. Antoniou A, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497-506 pubmed publisher
    ..Germline loss-of-function mutations in PALB2 are known to confer a predisposition to breast cancer. However, the lifetime risk of breast cancer that is conferred by such mutations remains unknown...
  3. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640-7 pubmed publisher
  4. Seo A, Lee H, Kim E, Kim H, Jang M, Lee H, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705-13 pubmed publisher
  5. Kucerova L, Skolekova S, Matuskova M, Bohac M, Kozovska Z. Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC Cancer. 2013;13:535 pubmed publisher
    ..The aim of our study was to characterize molecular changes dictated by adipose tissue-derived mesenchymal stromal cells (AT-MSCs) and the effects on drug responses in human breast cancer cells SKBR3...
  6. Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjønneland A, et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort. Int J Cancer. 2014;134:1947-57 pubmed publisher
  7. Robinson D, Wu Y, Vats P, Su F, Lonigro R, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446-51 pubmed publisher
    ..Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy. ..
  8. Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res Treat. 2013;142:227-35 pubmed publisher
    ..00001) and rate of BCS (from 35.4 to 54.8 %; OR = 2.1, 95 % CI 1.8-2.45, P < 0.00001) compared to ILC. The overall pCR rates and BCS decreased in the ILCs compared with IDC when treated with neoadjuvant chemotherapy. ..
  9. Nik Zainal S, Wedge D, Alexandrov L, Petljak M, Butler A, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46:487-91 pubmed publisher

More Information


  1. Cuzick J, Sestak I, Forbes J, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041-8 pubmed publisher
    ..Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca. ..
  2. Lee J, Lee J, Farquhar K, Yun J, Frankenberger C, Bevilacqua E, et al. Network of mutually repressive metastasis regulators can promote cell heterogeneity and metastatic transitions. Proc Natl Acad Sci U S A. 2014;111:E364-73 pubmed publisher
    ..Together, our results suggest that the mutually repressive relationship between metastatic regulators such as RKIP and BACH1 can play a key role in determining metastatic progression in cancer. ..
  3. His M, Zelek L, Deschasaux M, Pouchieu C, Kesse Guyot E, Hercberg S, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29:119-32 pubmed publisher
  4. Chajes V, Romieu I. Nutrition and breast cancer. Maturitas. 2014;77:7-11 pubmed publisher
    ..Successful development of breast cancer prevention strategies will require identification of biological markers of dietary exposure, and to coordinate worldwide research to discern the effects of diet. ..
  5. Clay M, Varma S, West R. MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions. Hum Pathol. 2013;44:2837-44 pubmed publisher
    ..Our findings suggest that these translocations occur during the transition to DCIS and/or invasive carcinoma. ..
  6. Pagani O, Regan M, Walley B, Fleming G, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107-18 pubmed publisher
    ..Funded by Pfizer and others; TEXT and SOFT numbers, NCT00066703 and NCT00066690, respectively.). ..
  7. Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72 pubmed publisher
    ..The prognostic value is greatest in aggressive tumour subtypes. Our pooled analysis could not validate pathological complete response as a surrogate endpoint for improved EFS and OS. US Food and Drug Administration. ..
  8. Kalinsky K, Crew K, Refice S, Xiao T, Wang A, Feldman S, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest. 2014;32:150-7 pubmed publisher
    ..We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients...
  9. Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C, et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014;510:167-71 pubmed publisher
    ..These findings demonstrate that centrosome amplification, a structural alteration of the cytoskeleton, can promote features of malignant transformation. ..
  10. Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik C, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111:984-9 pubmed publisher
    ..The results suggest that breast cancers exhibit neural characteristics when occupying the brain microenvironment and co-opt GABA as an oncometabolite. ..
  11. Bardowell S, Parker J, Fan C, Crandell J, Perou C, Swift Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat. 2013;142:365-80 pubmed publisher
    ..These findings highlight the need to control for subtype when interpreting DNA methylation results, and the importance of interrogating multiple CpGs across varied gene regions. ..
  12. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52-62 pubmed publisher
    ..Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population...
  13. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15:267-74 pubmed publisher
    ..Breast cancer is characterised by genomic alterations. We did a multicentre molecular screening study to identify abnormalities in individual patients with the aim of providing targeted therapy matched to individuals' genomic alterations...
  14. KROP I, Kim S, Gonzalez Martin A, LoRusso P, Ferrero J, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689-99 pubmed publisher
    ..We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients...
  15. Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149:267-74 pubmed publisher
    ..To our knowledge, there are no recent studies that directly compare survival after breast conservation therapy (BCT) vs mastectomy...
  16. Ciruelos Gil E. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40:862-71 pubmed publisher
  17. Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer. 2014;110:1053-7 pubmed publisher
    ..CDH1 mutation screening should be considered in women with early onset of bilateral LCIS/ILC with no family history of HDGC. ..
  18. Albuquerque R, Baltar V, Marchioni D. Breast cancer and dietary patterns: a systematic review. Nutr Rev. 2014;72:1-17 pubmed publisher
    ..Diets that include alcoholic beverages may be associated with increased risk. ..
  19. Lyman G, Temin S, Edge S, Newman L, Turner R, Weaver D, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365-83 pubmed publisher
  20. Cheung K, Gabrielson E, Werb Z, Ewald A. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell. 2013;155:1639-51 pubmed publisher
    ..Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression. ..
  21. Cummings M, Simpson P, Reid L, Jayanthan J, Skerman J, Song S, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232:23-31 pubmed publisher
  22. Fan L, Strasser Weippl K, Li J, St Louis J, Finkelstein D, Yu K, et al. Breast cancer in China. Lancet Oncol. 2014;15:e279-89 pubmed publisher
    ..Finally, we recommend key measures that could contribute to improved health outcomes for patients with breast cancer in China. ..
  23. Shim S, Park W, Huh S, Choi D, Shin K, Lee N, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88:65-72 pubmed publisher
    ..The purpose of this study was to investigate the role of postmastectomy radiation therapy (PMRT) after neoadjuvant chemotherapy (NAC) in clinical stage II-III breast cancer patients with pN0...
  24. Horlings H, Weigelt B, Anderson E, Lambros M, Mackay A, Natrajan R, et al. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat. 2013;142:257-69 pubmed publisher
  25. D Anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, et al. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. 2013;4:e891 pubmed publisher
    ..Taken together, our data suggest a possible use of parthenolide for the treatment of TNBCs...
  26. Thackeray R, Burton S, Giraud Carrier C, Rollins S, Draper C. Using Twitter for breast cancer prevention: an analysis of breast cancer awareness month. BMC Cancer. 2013;13:508 pubmed publisher
    ..However, there is a dearth of literature about how social media is used during awareness-related events. The purpose of this research was to understand how Twitter is being used during BCAM...
  27. Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, et al. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget. 2013;4:1829-35 pubmed
    ..Overall, we conclude that a p62-encoding vector(s) constitute(s) a novel, effective broad-spectrum antitumor and anti-metastatic vaccine feasible for further development and clinical trials. ..
  28. Couch F, Nathanson K, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343:1466-70 pubmed publisher
  29. Banys M, Solomayer E, Gebauer G, Janni W, Krawczyk N, Lueck H, et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer. 2013;13:480 pubmed publisher
    ..This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid (ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068)...
  30. Suman S, Das T, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109:2587-96 pubmed publisher
  31. Harbeck N, Sotlar K, Wuerstlein R, Doisneau Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev. 2014;40:434-44 pubmed publisher
  32. Prat A, Karginova O, Parker J, Fan C, He X, Bixby L, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 2013;142:237-55 pubmed publisher
    ..The results presented here help to improve our understanding of the wide range of breast cancer cell line models through the appropriate pairing of cell lines with relevant in vivo tumor and normal cell counterparts. ..
  33. Sharma V, Eddy R, Entenberg D, Kai M, Gertler F, Condeelis J. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Curr Biol. 2013;23:2079-89 pubmed publisher
    ..Tks5 regulates invadopodium formation, but the precise timing during invadopodium lifetime (initiation, stabilization, maturation) when Tks5 plays a role is not known...
  34. Vaidya J, Wenz F, Bulsara M, Tobias J, Joseph D, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603-13 pubmed publisher
    ..We report 5-year results for local recurrence and the first analysis of overall survival...
  35. Edwards B, Noone A, Mariotto A, Simard E, Boscoe F, Henley S, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290-314 pubmed publisher
    ..This year's report includes the prevalence of comorbidity at the time of first cancer diagnosis among patients with lung, colorectal, breast, or prostate cancer and survival among cancer patients based on comorbidity level...
  36. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269-77 pubmed publisher
    ..However, its ability to control for recurrence of local disease required confirmation in a randomised controlled trial...
  37. Charafe Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 2013;73:7290-300 pubmed publisher
    ..Our work offers a proof of the functional importance of CSCs in breast cancer, and it establishes the reliability of PDXs for use in developing personalized CSC therapies for patients with breast cancer...
  38. Giordano S, Temin S, Kirshner J, Chandarlapaty S, Crews J, Davidson N, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-99 pubmed publisher
    ..To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer...
  39. Toy W, Shen Y, Won H, Green B, Sakr R, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439-45 pubmed publisher
    ..These data implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit. ..
  40. Mulrane L, McGee S, Gallagher W, O Connor D. miRNA dysregulation in breast cancer. Cancer Res. 2013;73:6554-62 pubmed publisher
    ..This review focuses on the area of miRNA dysregulation in breast cancer through both genetic and epigenetic mechanisms, and the impact of this dysregulation on breast cancer risk and resistance to therapies...
  41. Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14:342-57 pubmed publisher
  42. Smith G, Jiang J, Buchholz T, Xu Y, Hoffman K, Giordano S, et al. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys. 2014;88:274-84 pubmed publisher
    ..3% vs 7.7%, P<.001). In this study era, brachytherapy showed lesser breast preservation benefit compared with EBRT. Suitability criteria predicted differential absolute, but not relative, benefit in patients with invasive cancer. ..
  43. Issa Nummer Y, Darb Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS ONE. 2013;8:e79775 pubmed publisher
    ..The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT...
  44. Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS ONE. 2013;8:e80707 pubmed publisher
    ..Together, these findings establish miR-150 as a novel regulator of P2X7 and a potential therapeutic target for breast cancer. ..
  45. Bidard F, Peeters D, Fehm T, Nole F, Gisbert Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15:406-14 pubmed publisher
    ..We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data...
  46. Buzdar A, Suman V, Meric Bernstam F, Leitch A, Ellis M, Boughey J, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r. Lancet Oncol. 2013;14:1317-25 pubmed publisher
    ..We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy...
  47. Rom J, Bechstein S, Domschke C, Golatta M, Mayer C, Heil J, et al. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. Anticancer Drugs. 2014;25:219-24 pubmed publisher
    ..A dosage of 40 mg/m² body surface every 4 weeks is equally effective with less toxicity...
  48. Gurunathan S, Raman J, Abd Malek S, John P, Vikineswary S. Green synthesis of silver nanoparticles using Ganoderma neo-japonicum Imazeki: a potential cytotoxic agent against breast cancer cells. Int J Nanomedicine. 2013;8:4399-413 pubmed publisher
    ..The aim of our study was to determine the cytotoxic effects of biologically synthesized AgNPs using hot aqueous extracts of the mycelia of Ganoderma neo-japonicum Imazeki on MDA-MB-231 human breast cancer cells...
  49. Polley M, Leung S, McShane L, Gao D, Hugh J, Mastropasqua M, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897-906 pubmed publisher
    ..A working group was assembled to devise a strategy to harmonize Ki67 analysis and increase scoring concordance. Toward that goal, we conducted a Ki67 reproducibility study...
  50. Nelson E, Wardell S, Jasper J, Park S, Suchindran S, Howe M, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094-8 pubmed publisher
    ..Thus, lowering circulating cholesterol levels or interfering with its conversion to 27HC may be a useful strategy to prevent and/or treat breast cancer. ..
  51. Earl H, Vallier A, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 . Lancet Oncol. 2014;15:201-12 pubmed publisher
  52. Valiente M, Obenauf A, Jin X, Chen Q, Zhang X, Lee D, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002-16 pubmed publisher
    ..By protecting cancer cells from death signals and fostering vascular co-option, anti-PA serpins provide a unifying mechanism for the initiation of brain metastasis in lung and breast cancers. ..
  53. Lillycrop K, Burdge G. Breast cancer and the importance of early life nutrition. Cancer Treat Res. 2014;159:269-85 pubmed publisher